Previous Close | 22,150.00 |
Open | 22,200.00 |
Bid | 22,350.00 x 0 |
Ask | 22,400.00 x 0 |
Day's Range | 22,100.00 - 22,550.00 |
52 Week Range | 19,040.00 - 30,600.00 |
Volume | |
Avg. Volume | 322,221 |
Market Cap | 1.031T |
Beta (5Y Monthly) | -1.17 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | May 10, 2024 - May 14, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 52,050.00 |
Seegene Inc., a leading South Korean company providing a total solution for PCR molecular diagnostics, announced today that Prof. Dame Jenny Harries, Chief Executive of the UK Health Security Agency (UKHSA), visited its headquarters located in Seoul Korea, on March 27.
Seegene Inc. (KQ096530), a leading South Korean company providing a total solution for PCR molecular diagnostics, and Springer Nature, a world-leading provider of services to the research community, unveiled the final list of participants for the diagnostic reagent development project on March 15, 2024(GMT), through the online platform of the Open Innovation Program (https://openinnovation.seegene.com/open-innovation/2023-2024-announcements/).
Seegene Inc. (KQ096530), a leading South Korean company providing a total solution for PCR molecular diagnostics, announced its selection of Microsoft as a technology partner for its SG OneSystemTM business in London, UK, on January 23 to realize 'a world free from all diseases.'